Denis Yaschenko

Denis Yaschenko has juvenile rheumatoid arthritis (JRA). Considering the high disease activity and progression, development of the hormone-dependency, growth retardation of the child and and noneffectiveness of long-term traditional antirheumatic therapy, Denis needs biological therapy with tocilizumab (Actemra). Funds for the purchase of the drug for Denis were transfered by the general partner of the fund "Beltransgaz."

Dear benefactors, if you want to receive the latest news about the activities of the Chance Foundation you can subscribe here, or join the official group of the Foundation in social networks: VKontakte, Twitter, Facebook.